Last reviewed · How we verify
Shigella4V2
At a glance
| Generic name | Shigella4V2 |
|---|---|
| Sponsor | LimmaTech Biologics AG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine (PHASE2)
- Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shigella4V2 CI brief — competitive landscape report
- Shigella4V2 updates RSS · CI watch RSS
- LimmaTech Biologics AG portfolio CI